Moderna (MRNA) Stock Forecast, Price & News

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 3 sell ratings, 9 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View MRNA analyst ratings or view top-rated stocks.

18 Wall Street analysts have issued 12 month price objectives for Moderna's shares. Their MRNA share price forecasts range from $93.00 to $296.00. On average, they anticipate the company's stock price to reach $155.52 in the next twelve months. This suggests a possible upside of 55.2% from the stock's current price.
View analysts price targets for MRNA or view top-rated stocks among Wall Street analysts.

Moderna's stock was trading at $179.62 at the beginning of the year. Since then, MRNA shares have decreased by 44.2% and is now trading at $100.23.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our MRNA earnings forecast.

Moderna, Inc. (NASDAQ:MRNA) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($3.62) EPS for the quarter, beating analysts' consensus estimates of ($3.84) by $0.22. The firm had revenue of $344 million for the quarter, compared to analysts' expectations of $307.67 million. Moderna had a trailing twelve-month return on equity of 6.62% and a net margin of 11.33%. The firm's revenue was down 92.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.24 EPS.

ETFs with the largest weight of Moderna (NASDAQ:MRNA) stock in their portfolio include Morningstar US Small Growth (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), iShares Genomics Immunology and Healthcare ETF (IDNA), ProShares Nanotechnology ETF (TINY) and iShares U.S. Tech Breakthrough Multisector ETF (TECB).

57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com. Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

(MRNA) raised $499 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 21,700,000 shares at $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

Moderna trades on the NASDAQ under the ticker symbol "MRNA."

Moderna's stock is owned by many different institutional and retail investors. Top institutional shareholders include Bank Julius Baer & Co. Ltd Zurich (37.35%), Baillie Gifford & Co. (11.99%), BlackRock Inc. (6.35%), State Street Corp (3.74%), Geode Capital Management LLC (1.66%) and Capital World Investors (1.04%). Insiders that own company stock include David W Meline, Dustin A Moskovitz, Juan Andres, Lori M Henderson, Lori M Henderson, Lori M Henderson, Mark D Mclaughlin, Noubar Afeyan, Paul Sagan, Shannon Thyme Klinger, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks and W Don Cornwell.
View institutional ownership trends.

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRNA stock can currently be purchased for approximately $100.23.

Moderna (NASDAQ:MRNA) has a market capitalization of $38.15 billion and generates $19.26 billion in revenue each year. The company earns $8.36 billion in net income (profit) each year or $2.71 on an earnings per share basis.

The company employs 3,900 workers across the globe.

Moderna's mailing address is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for the company is www.modernatx.com. The company can be reached via phone at (617) 714-6500 or via email at ir@modernatx.com.